Elarofiban (diTFA)

• Description :

  Elarofiban diTFA is the salt form of Elarofiban (HY-10315) with two TFA. Elarofiban diTFA is a nonpeptide, orally active antagonist for fibrinogen receptor αIIbβ3 (GPIIb/IIIa), with an IC50 of 0.15 nM. Elarofiban diTFA has the potential for platelet mediated thrombotic disorders research[1][2].

• CAS Number :

  [198958-89-3]

• UNSPSC :

  12352005

• Target :

  Integrin

• Type :

  Reference compound

• Related Pathways :

  Cytoskeleton

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/elarofiban-ditfa.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(N[C@H](C1=CN=CC=C1)CC(O)=O)[C@H]2CN(CCC2)C(CCC3CCNCC3)=O.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O

• Molecular Formula :

  C26H34F6N4O8

• Molecular Weight :

  644.56

• References & Citations :

  [1]Judith H. Cohen, et al. A Practical Synthesis of the Platelet Fibrinogen Antagonist, Elarofiban. Organic Process Research & Development 2003, 7, 866-872.|[2]De Corte BL, et al., Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins. Bioorg Med Chem Lett. 2004 Oct 18;14 (20) :5227-32.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported